Figure 2
Figure 2. OS, EFS, and c-CCyRS in the whole population and according to the cytogenetic response at 12 months. (A) Probabilities of OS (gray solid line), EFS (black broken line), and c-CCyRS (black solid line) in the whole population. The 4-year probability of OS, EFS, and c-CCyRS were 81.9%, 35.3%, and 54.4%, respectively. The figure shows how the EFS continues to decline over time, whereas the c-CCyRS plateaued at approximately 55% after the first year of therapy, reflecting that the responses are stable once they have been achieved. (B) EFS (broken line) and c-CCyRS (solid line) according to the cytogenetic response achieved at 12 months. The 48 patients who were in CCyR at 12 months, represented in black, had a 4-year probability of EFS of 71.8%; conversely, these patients had an excellent 4-year probability of c-CCyRS of 90%. In contrast, the 51 patients who were not in CCyR at 12 months, represented in gray, had a EFS of 5.6% (P < .001) and a c-CCyRS of 7.5% (P = .008)

OS, EFS, and c-CCyRS in the whole population and according to the cytogenetic response at 12 months. (A) Probabilities of OS (gray solid line), EFS (black broken line), and c-CCyRS (black solid line) in the whole population. The 4-year probability of OS, EFS, and c-CCyRS were 81.9%, 35.3%, and 54.4%, respectively. The figure shows how the EFS continues to decline over time, whereas the c-CCyRS plateaued at approximately 55% after the first year of therapy, reflecting that the responses are stable once they have been achieved. (B) EFS (broken line) and c-CCyRS (solid line) according to the cytogenetic response achieved at 12 months. The 48 patients who were in CCyR at 12 months, represented in black, had a 4-year probability of EFS of 71.8%; conversely, these patients had an excellent 4-year probability of c-CCyRS of 90%. In contrast, the 51 patients who were not in CCyR at 12 months, represented in gray, had a EFS of 5.6% (P < .001) and a c-CCyRS of 7.5% (P = .008)

Close Modal

or Create an Account

Close Modal
Close Modal